GLP1R and type 2 diabetes mellitus: In this large population-based cohort study comparing risk of all-cause mortality and MACE in new users of GLP-1-RAs or DPP-4is with IMIDs and type 2 diabetes, we found a 52% relative risk reduction in all-cause mortality and 34% relative risk reduction in MACE with GLP-1-RA exposure.